A Decade of Blood Biomarkers for Alzheimer’s Disease Research: An Evolving Field, Improving Study Designs, and the Challenge of Replication
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Blood-based biomarkers represent a less invasive and potentially cheaper approach for aiding Alzheimer’s disease (AD) detection compared with cerebrospinal fluid and some neuroimaging biomarkers. Acknowledging that many in the field have made great progress, here we review some of the work that our group has pursued to identify and validate blood-based proteomic biomarkers through both case control and AD pathology endophenotype-based approaches. Our focus is primarily to identify a minimally invasive and hopefully cost-effective blood-based biomarker to reduce screen failure in clinical trials where participants have prodromal or even pre-clinical disease. We summarize some of the key findings and approaches taken in these biomarker studies, while addressing the main challenges, including that of limited replication in the field, and discuss opportunities for biomarker development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164 · cited 1×
“A plaque burden, increased levels of tau in CSF, and brain atrophy are detected 15 years before expected symptom onset while global cognitive impairment is detected 5 years before symptom onset [39, 40], suggesting that such a study design could be effective in detecting blood-based biomarkers for preclinical disease.”
BackgroundClinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814 · cited 1×
“…levels of tau in CSF, and brain atrophy are detected 15 years before expected symptom onset while global cognitive impairment is detected 5 years before symptom onset [39, 40], suggesting that such a study design could be effective in detecting blood-based biomarkers for preclinical disease.”
BackgroundHarold, D., Abraham, R., Hollingworth, P., Sims, R., Gerrish, A., Hamshere, M. L., Pahwa, J. S., Moskvina, V., Dowzell, K., Williams, A., et al. (2009) · Nature Genetics · doi:10.1038/ng.440 · Cited by 3,326
Self-citationGenome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease
the European Alzheimer's Disease Initiative Investigators, Lambert, J.-C., Heath, S., Even, G., Campion, D., Sleegers, K., Hiltunen, M., Combarros, O., Zelenika, D., Bullido, M. J., et al. (2009) · Nature Genetics · doi:10.1038/ng.439 · Cited by 2,234
Olsson, B., Lautner, R., Andreasson, U., Öhrfelt, A., Portelius, E., Bjerke, M., Hölttä, M., Rosén, C., Olsson, C., Strobel, G., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00070-3 · Cited by 2,049
Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins
Ray, S., Britschgi, M., Herbert, C., Takeda-Uchimura, Y., Boxer, A., Blennow, K., Friedman, L. F., Galasko, D. R., Jutel, M., Karydas, A., et al. (2007) · Nature Medicine · doi:10.1038/nm1653 · Cited by 1,048 · cited 1×
“published soon after [16], persuaded us that there is a signal in blood; but the question remains, can that signal be translated to a replicable and useful biomarker?”
BackgroundBonini, P., Plebani, M., Ceriotti, F., & Rubboli, F. (2002) · Clinical Chemistry · doi:10.1093/clinchem/48.5.691 · Cited by 850
Jones, L., Holmans, P. A., Hamshere, M. L., Harold, D., Moskvina, V., Ivanov, D., Pocklington, A., Abraham, R., Hollingworth, P., Sims, R., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013950 · Cited by 606
Self-citationThambisetty, M., Simmons, A., Velayudhan, L., Hye, A., Campbell, J., Zhang, Y., Wahlund, L.-O., Westman, E., Kinsey, A., Güntert, A., et al. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.78 · Cited by 405
Self-citationSnowden, S. G., Ebshiana, A. A., Hye, A., An, Y., Pletnikova, O., O’Brien, R., Troncoso, J., Legido-Quigley, C., & Thambisetty, M. (2017) · PLOS Medicine · doi:10.1371/journal.pmed.1002266 · Cited by 309 · cited 1×
“A series of studies, including some from our own laboratories [67, 73–78], are beginning to nominate metabolite or lipidomic markers from blood and then there are other genomics including microRNAs and epigenetic changes, transcriptomics, and other markers.”
ResultSelf-citation
Research works printed but not linked: 57
- 10.1016/j.jalz.2011.03.005 · DOI · Paper page
- 10.1016/j.jalz.2011.03.008 · DOI · Paper page
- 10.1016/j.jalz.2011.03.003 · DOI · Paper page
- 10.1111/j.1526-4610.2011.01959.x · DOI · Paper page
- 10.1016/j.pneurobio.2012.06.007 · DOI
- 10.1111/j.1755-5949.2009.00104.x · DOI · Paper page
- 10.1002/acn3.313 · DOI
- 10.2174/1567205013666151116130301 · DOI
- 10.3389/fneur.2015.00236 · DOI · Paper page
- 10.1016/j.jalz.2013.01.013 · DOI · Paper page
- 10.1093/brain/awl279 · DOI · Paper page
- 10.1097/WNR.0000000000000661 · DOI
- 10.3233/JAD-142742 · DOI
- 10.1080/13547500802445199 · DOI · Paper page
- 10.1038/mp.2016.206 · DOI · Paper page
- 10.3233/JAD-2012-112012 · DOI · Paper page
- 10.1007/s00415-008-0006-8 · DOI
- Fyfe I, 2017, Nat Rev Neurol, 13, 5
- 10.3233/JAD-2010-100279 · DOI · Paper page
- 10.1186/1477-5956-12-5 · DOI
- 10.1016/j.neulet.2015.04.014 · DOI
- 10.1001/archneurol.2012.1282 · DOI · Paper page
- 10.1001/archneurol.2010.215 · DOI · Paper page
- 10.3233/JAD-160420 · DOI · Paper page
- 10.1186/1479-5876-10-217 · DOI · Paper page
- 10.1002/gps.1810 · DOI · Paper page
- 10.1021/acs.jproteome.5b00892 · DOI
- 10.1016/j.neuroimage.2011.07.056 · DOI · Paper page
- 10.1016/j.jalz.2014.05.1749 · DOI · Paper page
- 10.3233/JAD-130380 · DOI · Paper page
- 10.3233/JAD-150036 · DOI · Paper page
- 10.1371/journal.pone.0028527 · DOI · Paper page
- 10.3233/JAD-2011-110611 · DOI
- 10.1111/j.1749-6632.2009.05066.x · DOI · Paper page
- 10.1016/j.neurobiolaging.2009.03.011 · DOI · Paper page
- 10.1038/nm1653 · DOI · Paper page
- 10.3233/JAD-140669 · DOI · Paper page
- 10.3233/JAD-2010-101350 · DOI · Paper page
- 10.1016/j.dadm.2014.11.005 · DOI · Paper page
- 10.3233/JAD-151155 · DOI
- 10.1093/clinchem/43.8.1348 · DOI · Paper page
- 10.1016/j.jalz.2014.08.099 · DOI · Paper page
- 10.4236/aad.2012.13007 · DOI
- 10.3233/CBM-2009-0137 · doi:10.3233/cbm-2009-0137
- 10.1038/nm.3466 · DOI · Paper page
- 10.1016/j.jalz.2015.12.008 · DOI · Paper page
- 10.1016/j.jalz.2017.01.020 · DOI · Paper page
- 10.1016/j.dadm.2016.09.003 · DOI · Paper page
- 10.1016/j.jalz.2017.01.003 · DOI
- 10.3233/JAD-150020 · DOI · Paper page
- 10.1038/mp.2013.40 · DOI
- 10.1038/tp.2015.205 · DOI
- 10.3233/JAD-160645 · DOI · Paper page
- 10.1016/j.neurobiolaging.2013.08.001 · DOI · Paper page
- 10.1016/j.jalz.2016.08.003 · DOI · Paper page
- 10.1038/tp.2014.127 · DOI · Paper page
- 10.1186/s13195-017-0258-6 · DOI
Cited by
Recent Advancements in Pathogenesis, Diagnostics and Treatment of Alzheimer’s Disease
Khan, S., Barve, K. H., & Kumar, M. S. (2020) · Current Neuropharmacology · doi:10.2174/1570159x18666200528142429 · Cited by 820
“Recently there has been a surge in finding blood biomarkers appropriate for repeated evaluations throughout the disease progression over a time-frame for an interventional/treatment study [57].”
BackgroundLarge-scale plasma proteomic analysis identifies proteins and pathways associated with dementia risk
Walker, K. A., Chen, J., Zhang, J., Fornage, M., Yang, Y., Zhou, L., Grams, M. E., Tin, A., Daya, N., Hoogeveen, R. C., et al. (2021) · Nature Aging · doi:10.1038/s43587-021-00064-0 · Cited by 212
Ashton, N. J., Leuzy, A., Karikari, T. K., Mattsson-Carlgren, N., Dodich, A., Boccardi, M., Corre, J., Drzezga, A., Nordberg, A., Ossenkoppele, R., et al. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05253-y · Cited by 142
Rahman, M. R., Islam, T., Zaman, T., Shahjaman, M., Karim, M. R., Huq, F., Quinn, J. M. W., Holsinger, R. M. D., Gov, E., & Moni, M. A. (2020) · Genomics · doi:10.1016/j.ygeno.2019.07.018 · Cited by 136
Further understanding the connection between Alzheimer's disease and Down syndrome
Snyder, H. M., Bain, L. J., Brickman, A. M., Carrillo, M. C., Esbensen, A. J., Espinosa, J. M., Fernandez, F., Fortea, J., Hartley, S. L., Head, E., et al. (2020) · Alzheimer's & Dementia · doi:10.1002/alz.12112 · Cited by 105
Metadata
- Authors
- Shi, L., Baird, A. L., Westwood, S., Hye, A., Dobson, R., Thambisetty, M., & Lovestone, S.
- Venue
- Journal of Alzheimer’s Disease
- Publisher
- SAGE Publications
- Published
- 2017-12-01
- Volume
- 62
- Issue
- 3
- Pages
- 1181-1198
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W2772836221
- Cited by
- 90
- References
- 22
- FWCI
- 9.17
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Decade of Blood Biomarkers for Alzheimer’s Disease Research: An Evolving Field, Improving Study Designs, and the Challenge of Replication. https://app.cochat.ai/papers/10.3233/jad-170531
- The paper
- Shi, L., Baird, A. L., Westwood, S., Hye, A., Dobson, R., Thambisetty, M., & Lovestone, S. (2018). A Decade of Blood Biomarkers for Alzheimer’s Disease Research: An Evolving Field, Improving Study Designs, and the Challenge of Replication. Journal of Alzheimer’s Disease. https://doi.org/10.3233/jad-170531
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.